Monday, November 7, 2022 Daily Archives

GEA breaks ground on $20m+ site in Wisconsin

GEA has started construction of its repair, logistics, assembly, production, and training facility located in Janesville, Wisconsin. According to the firm, the 85,000 square-foot building – which is GEA’s first greenfield site in North America in 50 years – aims to bring the company closer to its Midwest customer base and service their industry needs. “The Janesville facility will bring us closer to our growing Midwest customer base and it will enable us to meet the growing demand for our…

ten23 looks to on-body-injectors to reduce healthcare costs

CDMO ten23 health is supporting customers to develop an on-body-injector platform, which it says could lower overall treatment costs. Ten23, a contract development manufacturing organization (CDMO) focused on developing and commercializing injectable biopharmaceuticals met BioProcess Insider at CPHI, Frankfurt to discuss its on-body-injector activity. “Instead of holding and keeping in position a syringe for the time of injection, on-body-injectors are stuck to the body,” explained Michael Petersen, ten23’s chief commercial officer. “A button is pressed, and a small motor is…

Galapagos goes hard on CAR-T in strategic restructure

Galapagos has announced a business restructure that includes trimming its fibrosis and kidney disease programs and axing 200 staff in favor of its immune-oncology pipeline. The ‘Forward, Faster’ strategy, announced in line with Galapagos’ third quarter 2022 results, aims to move the Belgian biopharma’s focus from novel target-based discovery to patient centric medical need R&D with a focus on immunology and oncology. As part of this, CEO Paul Stoffels stressed the firm will “build on our current capabilities and derisk…

JW partners with 2seventy to develop T Cell immunotherapies

Shanghai JW Therapeutics will partner with Boston’s 2seventy bio to use 2seventy’s cell therapy platform to develop T cell-based immunotherapies for Greater China. The collaboration will focus initially on 2seventy bio’s MAGE-A4 TCR program in solid tumors. JW will be responsible for development, manufacturing, and commercialization within China. 2seventy bio will receive milestones and royalty payments on revenues in China, and 2seventy may use JW’s clinical data to support ex-China development. Financial details of the agreement were not disclosed. JW…